CAS: 884512-77-0; (R)-4-(Tert-Butoxycarbonyl)Morpholine-2-Carboxylic Acid

英文名称(R)-4-(Tert-Butoxycarbonyl)Morpholine-2-Carboxylic Acid
中文名称(2R)-2,4-吗啉二羧酸4-叔丁酯
IUPAC名称(R)-4-(tert-butoxycarbonyl)morpholine-2-carboxylic acid
其它别名(R)-4-Boc-吗啉-2-羧酸 4-叔丁酯; (R)-N-Boc-2-Morpholinecarboxylic Acid
CAS编号884512-77-0
MFCD编号:MFCD09260604
EINECS号:828-635-6
分子式:C10H17NO5
分子量:231.25
产品CID: 1895426
产品分类有机原料→分子砌块→脂肪杂环类化合物→吗啉类化合物

相似结构搜索
InChIKey: LGWMTRPJZFEWCX-SSDOTTSWSA-N
InChI=1S/C10H17NO5/c1-10(2,3)16-9(14)11-4-5-15-7(6-11)8(12)13/h7H,4-6H2,1-3H3,(H,12,13)/t7-/m1/s1…
计算化学: 氢键受体数4.0氢键供体数1.0可旋转键数1.0

相似化合物

868689-63-8 189321-66-2 769087-80-1

MSDS等安全信息

GHS符号GHS07
危险类别水生慢性毒性类别2
严重眼刺激类别2A
警示词Warning
危险描述H411 |对水生生物有毒并具有长期持续影响.
H319 |造成严重眼刺激.
防范说明P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
危险品标志Xi
安全声明H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body

欧盟法规

C&L通报

上下游产品

CAS号135065-71-3 (R)-N-B°C-2-羟甲基吗啉 | CAS号135065-70-2 (R)-2-((苄氧基)甲基)吗啉 | CAS号24424-99-5 二碳酸二叔丁酯 | CAS号135065-71-3 (R)-N-B°C-2-羟甲基吗啉

合成工艺路线路线简述

135065-71-3 = 884512-77-0
反应条件:1.1 Reagents: Trichloroisocyanuric Acid,Sodium Bicarbonate,Tempo,Sodium Bromide Solvents: Acetone
标题:Biphenyl/diphenyl Ether Renin Inhibitors: Filling The S1 Pocket Of Renin Via The S3 Pocket
作者:Yuan,Jing; Et Al
参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2011 卷标:21(16) 页码:4836-4843]

24424-99-5 + 1212396-52-5 = 884512-77-0
反应条件:1.1 Reagents: Sodium Bicarbonate Solvents: Tetrahydrofuran,Water; Overnight,25 °C1.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 2,25 °C
标题:Design,Synthesis And Biological Evaluation Of Protease Inhibitors Containing Morpholine Cores With Remarkable Potency Against Both Hiv-1 Subtypes B And C
作者:Zhu,Mei; Et Al
参考文献:European Journal Of Medicinal Chemistry 日期:2022 卷标:233]

1030837-47-8 = 884512-77-0
反应条件:1.1 Catalysts: Triacylglycerol Lipase Solvents: Tert-Butyl Methyl Ether,Water; 24 - 30 H,Rt2.1 Reagents: 1-Methyl-1,4-Cyclohexadiene Catalysts: Palladium Solvents: Ethanol; Reflux
标题:Enantioselective Synthesis Of (R)- And (S)-N-Boc-Morpholine-2-Carboxylic Acids By Enzyme-Catalyzed Kinetic Resolution: Application To The Synthesis Of Reboxetine Analogs
作者:Fish,Paul V.; Et Al
参考文献:Tetrahedron Letters 日期:2009 卷标:50(4) 页码:389-391]

24424-99-5 = 884512-77-0
反应条件:1.1 Reagents: 1-Methyl-1,4-Cyclohexadiene Catalysts: Palladium Solvents: Ethanol; Reflux
标题:Enantioselective Synthesis Of (R)- And (S)-N-Boc-Morpholine-2-Carboxylic Acids By Enzyme-Catalyzed Kinetic Resolution: Application To The Synthesis Of Reboxetine Analogs
作者:Fish,Paul V.; Et Al
参考文献:Tetrahedron Letters 日期:2009 卷标:50(4) 页码:389-391]

135097-68-6 = 884512-77-0
反应条件:1.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol; Rt2.1 Reagents: Trichloroisocyanuric Acid,Sodium Bicarbonate,Tempo,Sodium Bromide Solvents: Acetone
标题:Biphenyl/diphenyl Ether Renin Inhibitors: Filling The S1 Pocket Of Renin Via The S3 Pocket
作者:Yuan,Jing; Et Al
参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2011 卷标:21(16) 页码:4836-4843]

126645-52-1 + 71-36-3 = 884512-77-0
反应条件:1.1 Reagents: Sulfuric Acid Solvents: 1-Butanol,Water; Reflux2.1 Catalysts: Triacylglycerol Lipase Solvents: Tert-Butyl Methyl Ether,Water; 24 - 30 H,Rt3.1 Reagents: 1-Methyl-1,4-Cyclohexadiene Catalysts: Palladium Solvents: Ethanol; Reflux
标题:Enantioselective Synthesis Of (R)- And (S)-N-Boc-Morpholine-2-Carboxylic Acids By Enzyme-Catalyzed Kinetic Resolution: Application To The Synthesis Of Reboxetine Analogs
作者:Fish,Paul V.; Et Al
参考文献:Tetrahedron Letters 日期:2009 卷标:50(4) 页码:389-391]

24424-99-5 + 135065-70-2 = 884512-77-0
反应条件:1.1 Reagents: Potassium Carbonate Solvents: Acetone,Water; 30 Min,0 °C -> Rt2.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol; Rt3.1 Reagents: Trichloroisocyanuric Acid,Sodium Bicarbonate,Tempo,Sodium Bromide Solvents: Acetone
标题:Biphenyl/diphenyl Ether Renin Inhibitors: Filling The S1 Pocket Of Renin Via The S3 Pocket
作者:Yuan,Jing; Et Al
参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2011 卷标:21(16) 页码:4836-4843]

14618-80-5 + 926-39-6 = 884512-77-0
反应条件:1.1 Reagents: Sodium Hydroxide Solvents: Methanol,Water; 2 H,40 °C1.2 Reagents: Sodium Hydroxide Solvents: Toluene,Water; 16 H,65 °C2.1 Reagents: Potassium Carbonate Solvents: Acetone,Water; 30 Min,0 °C -> Rt3.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol; Rt4.1 Reagents: Trichloroisocyanuric Acid,Sodium Bicarbonate,Tempo,Sodium Bromide Solvents: Acetone
标题:Biphenyl/diphenyl Ether Renin Inhibitors: Filling The S1 Pocket Of Renin Via The S3 Pocket
作者:Yuan,Jing; Et Al
参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2011 卷标:21(16) 页码:4836-4843

(R)-N-Boc-2-羟甲基吗啉置于碳酸氢钠,2,2,6,6-四甲基哌啶氧化物,三氯异氰尿酸,Sodium Bromide体系中,用丙酮作为反应溶剂,以92%的收率获得产物(2R)-2,4-吗啉二羧酸 4-叔丁酯
参考文献:Renin Inhibitors
标题:Renin Inhibitors
摘要:揭示了具有以下化学式(I)的化合物:其中r1,R2,R3,X,Y,A,L和g在此处被定义.这些化合物结合到天冬氨酸蛋白酶上以抑制其活性,并且在治疗或改善与天冬氨酸蛋白酶活性相关的疾病中很有用.还揭示了使用化合物i的方法,用于改善或治疗需要的患有天冬氨酸蛋白酶相关疾病的受试者.

海关参考信息

2905122000-异丙醇
2905143000-叔丁醇
2905310000-1,2-乙二醇
2905320000-1,2-丙二醇
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:US-2024309003-A1
优先权日:2021-05-04
标题 :Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：HOUZE JONATHAN B; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN; PANDYA BHAUMIK; KAPLAN ALAN
权利人:VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (â€œTREM2â€?). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:US-8487108-B2
优先权日:2005-11-14
标题 :Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors
发明人：BALDWIN JOHN J; CLAREMON DAVID A; TICE COLIN; CACATIAN SALVACION; DILLARD LAWRENCE W; ISHCHENKO ALEXEY V; YUAN JING; XU ZHENRONG; MCGEEHAN GERARD; SIMPSON ROBERT D; SINGH SURESH B; ZHAO WEI; FLAHERTY PATRICK T
权利人:BALDWIN JOHN J; CLAREMON DAVID A; TICE COLIN; CACATIAN SALVACION; DILLARD LAWRENCE W; ISHCHENKO ALEXEY V; YUAN JING; XU ZHENRONG; MCGEEHAN GERARD; SIMPSON ROBERT D; SINGH SURESH B; ZHAO WEI; FLAHERTY PATRICK T; VITAE PHARMACEUTICALS INC
摘要:The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.